Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged versus routine intravesical epirubicin after TURBT for moderate- or high-risk non-muscle-invasive bladder cancer
ChiCTR-IPR-17011476Phase 4Not yet recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: 3-year recurrence rate. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
epirubicin
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR-IPR-17011476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011476.